Literature DB >> 7107004

Virus inoculation in mice bearing Ehrlich ascitic tumors: antigen production and tumor regression.

N E Mettler, D H Clarke, J Casals.   

Abstract

Ehrlich ascitic carcinoma, as developed in albino mice, has been used as a source of hemagglutinating and complement-fixing antigens, and it proved to be suitable for one type of antigen, or both, for at least 12 viruses of 16 tested. Hemagglutinins were obtained with members of arbovirus groups A, B, and C; complement-fixing antigens were obtained for at least one member of each antigenic group tested. Ehrlich ascitic tumor was compared with sarcoma 180 as a source of antigens; although sarcoma 180 showed many advantages over Ehrlich tumor, the latter gave, in general, better results for complement-fixing antigens. Oncolytic effect with complete recovery of the mice was observed in some instances. The highest recovery rate resulted with Congo and UNA viruses (40%), and the second highest rate resulted with dengue 2, St. Louis, Hazara, and Uukuniemi viruses (20%). The best survival was observed, in decreasing order, with Congo, St. Louis, dengue 2, Tacaribe, Sindbis, Junin, and Amapari viruses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107004      PMCID: PMC347484          DOI: 10.1128/iai.37.1.23-27.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  6 in total

1.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

2.  Ascites tumors as culture media in quantitative growth studies of viral agents.

Authors:  H KOPROWSKI
Journal:  Ann N Y Acad Sci       Date:  1956-03-14       Impact factor: 5.691

3.  Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses.

Authors:  D H CLARKE; J CASALS
Journal:  Am J Trop Med Hyg       Date:  1958-09       Impact factor: 2.345

4.  Use of sarcoma 180 to prepare hemagglutinating and complement-fixing antigens for viruses in adult mice.

Authors:  N E Mettler; J Casals; D H Clarke; W G Downs; R E Shope
Journal:  Proc Soc Exp Biol Med       Date:  1971-04

5.  Cytolytic activity of arboviruses in murine leukemic lymphoblasts.

Authors:  T B Stim; G A Fischer; W G Downs; M Y Chu
Journal:  Cancer Chemother Rep 2       Date:  1971-04

6.  Isolation of a microtatobiote from patients with hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura and from mites in the United States.

Authors:  N E Mettler
Journal:  N Engl J Med       Date:  1969-11-06       Impact factor: 91.245

  6 in total
  4 in total

1.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

2.  Immune recognition of tumor cells in mice infected with Pichinde virus.

Authors:  N Molomut; M Padnos; T W Papperman; D C Pevear; C J Pfau
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 3.  Potential of oncolytic viruses in the treatment of multiple myeloma.

Authors:  Eric Bartee
Journal:  Oncolytic Virother       Date:  2018-02-23

Review 4.  Oncolytic viruses in cancer therapy.

Authors:  Markus J V Vähä-Koskela; Jari E Heikkilä; Ari E Hinkkanen
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.